stoxline Quote Chart Rank Option Currency Glossary
  
BioNexus Gene Lab Corp. (BGLC)
0.479  0.009 (1.91%)    06-13 16:00
Open: 0.483
High: 0.4991
Volume: 79,755
  
Pre. Close: 0.47
Low: 0.46
Market Cap: 8(M)
Technical analysis
2024-06-13 4:41:53 PM
Short term     
Mid term     
Targets 6-month :  0.72 1-year :  0.87
Resists First :  0.62 Second :  0.75
Pivot price 0.5
Supports First :  0.41 Second :  0.34
MAs MA(5) :  0.5 MA(20) :  0.51
MA(100) :  0.63 MA(250) :  0.8
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  20.5 D(3) :  26.7
RSI RSI(14): 41.7
52-week High :  9.48 Low :  0.15
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BGLC ] has closed above bottom band by 37.8%. Bollinger Bands are 50.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.5 - 0.5 0.5 - 0.51
Low: 0.45 - 0.46 0.46 - 0.46
Close: 0.47 - 0.48 0.48 - 0.48
Company Description

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Headline News

Thu, 13 Jun 2024
BioNexus Gene Lab Corp. (NASDAQ:BGLC) Short Interest Down 44.8% in May - Defense World

Wed, 12 Jun 2024
12 Industrials Stocks Moving In Wednesday's Intraday Session - BioNexus Gene Lab (NASDAQ:BGLC), Montana ... - Benzinga

Fri, 07 Jun 2024
Psychemedics (NASDAQ:PMD) and BioNexus Gene Lab (NASDAQ:BGLC) Head to Head Analysis - Defense World

Fri, 19 Apr 2024
Why Is BioNexus Gene Lab (BGLC) Stock Down 27% Today? - InvestorPlace

Thu, 18 Apr 2024
BioNexus Gene Lab Expands Reach with Strategic Investment - TipRanks.com - TipRanks

Thu, 18 Apr 2024
BioNexus Gene Lab Invests in AI Healthcare Company - MarketWatch

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Shares Out 18 (M)
Shares Float 10 (M)
Held by Insiders 64.3 (%)
Held by Institutions 0.5 (%)
Shares Short 106 (K)
Shares Short P.Month 100 (K)
Stock Financials
EPS -0.19
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.52
Profit Margin -27.3 %
Operating Margin -3.4 %
Return on Assets (ttm) -13.4 %
Return on Equity (ttm) -33.5 %
Qtrly Rev. Growth 0.2 %
Gross Profit (p.s.) 0
Sales Per Share 0.55
EBITDA (p.s.) -0.12
Qtrly Earnings Growth 0 %
Operating Cash Flow -1 (M)
Levered Free Cash Flow 1 (M)
Stock Valuations
PE Ratio -2.53
PEG Ratio 0
Price to Book value 0.9
Price to Sales 0.86
Price to Cash Flow -6.94
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android